Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
- Conditions
- Advanced Solid TumorLymphoma
- Interventions
- Drug: T-1301 Capsules
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Taivex Therapeutics Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT05156203
- Locations
- π¨π³
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
π¨π³Taipei Veterans General Hospital, Taipei City, Taiwan
π¨π³ChangGung Memorial Hospital, Linkou, Taoyuan City, Taiwan
Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: T-1201 Injection 100 mg Kit
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Taivex Therapeutics Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT04866641
- Locations
- π¨π³
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
π¨π³National Cheng Kung University Hospital, Tainan, Taiwan
Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
- Conditions
- Advanced Refractory Solid Tumors
- Interventions
- Drug: T-1101 (Tosylate)
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Taivex Therapeutics Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT04685473
- Locations
- π¨π³
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
π¨π³National Cheng Kung University Hospital, Tainan, Taiwan
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
- Conditions
- Advanced Refractory Solid Tumors
- Interventions
- Drug: T-1101 (Tosylate)
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Taivex Therapeutics Corporation
- Target Recruit Count
- 3
- Registration Number
- NCT03349073
- Locations
- π¨π³
China Medical University Hospital, Taichung City, Taiwan
π¨π³National Cheng Kung University (NCKU) Hospital, Tainan, Taiwan
π¨π³Taipei Medical University Hospital, Taipei, Taiwan
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
- Conditions
- Advanced Refractory Solid Tumors
- Interventions
- Drug: T-1101 (Tosylate)
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Taivex Therapeutics Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT03195764
- Locations
- π¨π³
China Medical University Hospital, Taichung City 404327, Taiwan
π¨π³National Cheng Kung University Hospital, Tainan, Taiwan
π¨π³Taipei Medical University Hospital, Taipei, Taiwan